Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence
暂无分享,去创建一个
A. Kapoor | M. Jewett | G. Bjarnason | C. Kollmannsberger | D. Heng | L. Wood | D. Soulières | M. Reaume | N. Basappa | E. Lévesque | A. Dragomir | S. Tanguay | S. Nazha | L. Wood
[1] A. Kapoor,et al. Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting. , 2018, Current oncology.
[2] C. Porta,et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups , 2017, Annals of Oncology.
[3] Dang M. Tran,et al. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. , 2017, Journal of managed care & specialty pharmacy.
[4] A. Kapoor,et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[5] T. Delea,et al. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. , 2016, Current oncology.
[6] C. Beauchemin,et al. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada , 2016, Journal of medical economics.
[7] T. Delea,et al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. , 2015, Journal of managed care & specialty pharmacy.
[8] C. Porta,et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Kiss,et al. Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.
[10] Y. Najjar,et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. , 2014, European journal of cancer.
[11] T. Bathala,et al. Adult UrologyOncology: Adrenal/Renal/Upper Tract/BladderClinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules , 2014 .
[12] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[13] R. Breau,et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[14] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.
[15] M. Drummond,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, BMJ.
[16] William Hollingworth,et al. Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[17] C. Barrios,et al. Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma , 2012, Cancer.
[18] I. Chabot,et al. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[19] David Cella,et al. Elicitation of health state utilities in metastatic renal cell carcinoma , 2010, Current medical research and opinion.
[20] W. Linehan,et al. Molecular diagnosis and therapy of kidney cancer. , 2010, Annual review of medicine.
[21] H. Verheul,et al. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? , 2009, Angiogenesis.
[22] C. Charbonneau,et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.
[23] Xu Zhang,et al. Erratum to "A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model" [Computer Methods and Programs in Biomedicine 88 (2007) 95-101] , 2008, Comput. Methods Programs Biomed..
[24] Xu Zhang,et al. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model , 2007, Comput. Methods Programs Biomed..
[25] S. Verma,et al. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis , 2006, Supportive Care in Cancer.
[26] W. Marston Linehan,et al. Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.
[27] S. Campbell,et al. Metastatic renal cell carcinoma , 2003, Current treatment options in oncology.
[28] A. Kiss,et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.